Aarti Drugs Ltd
Thu 13/03/2025,15:54:22 | NSE : AARTIDRUGS
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 340.20
Previous Close
₹ 340.20
Volume
238464
Mkt Cap ( Rs. Cr)
₹3105.01
High
₹ 344.85
Low
₹ 332.30
52 Week High
₹ 635.00
52 Week Low
₹ 332.30
Book Value Per Share
₹ 139.96
Dividend Yield
0.29
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Aarti Drugs Ltd
Your Vote -
Buy
51.83%
Hold
27.24%
Sell
20.92%
51.83%
1472 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
340.20
933
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
933
Option Chain
Analyzes market sentiment, predicts Aarti Drugs Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Aarti Drugs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Aarti Drugs Ltd - Action(s) taken or orders passed
-
Aarti Drugs Ltd - Action(s) taken or orders passed
-
Aarti Drugs Ltd - Announcement Under Regulation 30 Of Listing Regulations - ESG Rating
-
Aarti Drugs Ltd - General Updates
-
Aarti Drugs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Aarti Drugs Ltd - Disclosure Under Reg 30 Of Listing Regulations - Update On Lifting Of Import Alert 66-40 By US DFA
-
Aarti Drugs Ltd - Action(s) taken or orders passed
-
Aarti Drugs Ltd - Disclosure Under Regulation 30 Of Listing Reguations- Order Of CGST And C.Ex. Authority
-
Aarti Drugs Ltd - Action(s) taken or orders passed
-
Aarti Drugs Ltd - Disclosure Under Regulation 30 Of Listing Regulations-
-
Aarti Drugs Ltd - Action(s) taken or orders passed
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Aarti Drugs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates
-
Aarti Drugs Ltd - General Updates
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Acquisition
-
Aarti Drugs Ltd - Acquisition-XBRL
-
Aarti Drugs Ltd - General Updates
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Acquisition
-
Aarti Drugs Ltd - Copy of Newspaper Publication
-
Aarti Drugs Ltd - Credit Rating
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Credit Rating
-
Aarti Drugs Ltd has declared 10% Interim dividend for the financial year March 2025
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Aarti Drugs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates
-
Aarti Drugs Ltd - Acquisition-XBRL
-
Aarti Drugs Ltd - Investor Presentation
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Aarti Drugs Ltd - Press Release
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Aarti Drugs Ltd - General Updates
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Acquisition
-
Aarti Drugs Ltd - Integrated Filing- Financial
-
Aarti Drugs Ltd - Integrated Filing (Financial)
-
Aarti Drugs Ltd Q3 net profit up 21.85% at Rs 38.53 cr
-
Aarti Drugs Ltd - Outcome of Board Meeting-XBRL
-
Aarti Drugs Ltd - Record Date
-
Aarti Drugs Ltd - Dividend
-
Aarti Drugs Ltd - Financial Results For The Quarter And Nine Months Ended December 31, 2024 And Interim Dividend
-
Aarti Drugs Ltd - Financial Result Updates
-
Aarti Drugs Ltd - Record Date For Interim Dividend
-
Aarti Drugs Ltd - Corporate Action-Board approves Dividend
-
Aarti Drugs Ltd - Board Meeting Outcome for Financial Results And Interim Dividend
-
Aarti Drugs Ltd - Disclosure Under Regulation 30 Of Listing Regulations
-
Aarti Drugs Ltd - Action(s) taken or orders passed
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Aarti Drugs Ltd - Analysts/Institutional Investor Meet/Con. Call Updates
-
Aarti Drugs Ltd - Board Meeting Intimation
-
Aarti Drugs Ltd - Board Meeting Intimation for Financial Results For The Quarter And Nine Months Ended December 31, 2024 And
-
Aarti Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024
-
Aarti Drugs Ltd - Acquisition-XBRL
-
Aarti Drugs Ltd - General Updates
-
Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Acquisition
-
Aarti Drugs Ltd - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Aarti Drugs Ltd - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Aarti Drugs Ltd - Trading Window-XBRL
-
Aarti Drugs Ltd - Trading Window
-
Aarti Drugs Ltd - Action(s) taken or orders passed
-
Aarti Drugs Ltd - Receipt Of US FDA EIR For Manufacturing Facility Of The Company
-
Aarti Drugs Ltd - Loss/Duplicate-Share Certificate-XBRL
-
Aarti Drugs Ltd - Loss of Share Certificates
-
ICRA reaffirms ratings of Aarti Drugs
-
Aarti Drugs board approves buyback worth up to Rs. 60 crore
-
Aarti Drugs to consider share buyback on March 19
-
Aarti Drugs
-
Aarti Drugs
-
Aarti Drugs fixes record date for bonus issue
-
Aarti Drugs board recommends bonus issue
-
Aarti Drugs surges in flat market
-
Aarti Drugs falls in strong market
-
Aarti Drugs gains on fixing record date for buyback
Key fundamentals
Evaluate the intrinsic value of Aarti Drugs Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 1648.0593 | 1647.387 | 1487.0525 | 1149.3541 | 952.6836 |
Liabilities | 1648.0593 | 1647.387 | 1487.0525 | 1149.3541 | 952.6836 |
Equity | 91.935 | 92.6 | 92.6 | 93.2 | 23.3 |
Gross Profit | 266.1306 | 282.4035 | 318.1833 | 401.2687 | 244.4082 |
Net Profit | 141.8827 | 152.8109 | 194.9982 | 257.7124 | 135.6747 |
Cash From Operating Activities | 337.1041 | 162.2824 | 39.896 | 154.0754 | 196.1475 |
NPM(%) | 6.25 | 6.11 | 8.66 | 13.45 | 8.29 |
Revenue | 2266.9114 | 2497.9704 | 2251.1743 | 1914.8903 | 1634.922 |
Expenses | 2000.7808 | 2215.5669 | 1932.991 | 1513.6216 | 1390.5138 |
ROE(%) | 11.1 | 11.96 | 15.26 | 20.17 | 10.62 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|---|---|---|---|
04 Feb 2025 | 1 | 10 | 0.29 | 396.7 |
06 Feb 2024 | 1 | 10 | 0.29 | 535.25 |
08 Feb 2023 | 1 | 10 | 0.29 | 410.15 |
09 Feb 2022 | 1 | 10 | 0.29 | 503.45 |
03 Nov 2020 | 2.5 | 25 | 0.29 | 750.3 |
17 Feb 2020 | 2 | 20 | 0.29 | 628.3 |
26 Jul 2019 | 1 | 10 | 0.29 | 602.7 |
01 Aug 2018 | 1 | 10 | 0.29 | 566.8 |
09 Aug 2017 | 1 | 10 | 0.29 | 482.4 |
22 Mar 2016 | 3 | 30 | 0.29 | 492.9 |
12 Feb 2016 | 1.5 | 15 | 0.29 | 527.5 |
10 Nov 2015 | 2.25 | 22.5 | 0.29 | 582.65 |
05 Aug 2015 | 3 | 30 | 0.29 | 738.6 |
04 Feb 2015 | 5 | 50 | 0.29 | 1051.2 |
19 Nov 2014 | 5 | 50 | 0.29 | 756.6 |
02 Jul 2014 | 5.5 | 55 | 0.29 | 357.7 |
05 Feb 2014 | 4.5 | 45 | 0.29 | 217.55 |
19 Nov 2013 | 3 | 30 | 0.29 | 193.2 |
24 Jul 2013 | 4 | 40 | 0.29 | 190.55 |
11 Feb 2013 | 3 | 30 | 0.29 | 221 |
05 Nov 2012 | 3 | 30 | 0.29 | 176.15 |
17 Aug 2012 | 3 | 30 | 0.29 | 100.9 |
06 Feb 2012 | 2 | 20 | 0.29 | 89.15 |
14 Jul 2011 | 2.5 | 25 | 0.29 | 128.65 |
07 Feb 2011 | 2.5 | 25 | 0.29 | 139.05 |
18 Aug 2010 | 5 | 50 | 0.29 | 118.1 |
23 Jul 2009 | 3 | 30 | 0.29 | 50.8 |
13 Aug 2008 | 1.8 | 18 | 0.29 | 51.75 |
20 Mar 2007 | 1.2 | 12 | 0.29 | 56.45 |
19 Jul 2006 | 1.5 | 15 | 0.29 | 88.7 |
27 Jul 2005 | 1.6 | 16 | 0.29 | 127.65 |
25 Jun 2004 | 1.8 | 18 | 0.29 | 79.25 |
13 Nov 2003 | 1.2 | 12 | 0.29 | 96.8 |
23 Oct 2001 | 0 | 10 | 0.29 | 17.5 |
11 Jun 2001 | 0 | 15 | 0.29 | 15.3 |
0 | 8 | 0.29 | 25.95 | |
0 | 7 | 0.29 | 33.35 | |
0 | 7 | 0.29 | 19 | |
0 | 11 | 0.29 | 13.5 | |
0 | 22 | 0.29 | 11.55 |
Peers
Other companies within the same industry or sector that are comparable to Aarti Drugs Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 808.20 | -1.14 | 11.41 | 194.99 | 1321.50 | 1.42 |
Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 710.51 | 14.01 | 0.88 |
Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 366.22 | 2.31 | 0.00 |
Astec Lifesciences Ltd | 653.90 | -5.55 | 0.00 | 669.95 | -239.30 | 0.00 |
Company Info
Aarti Drugs Limited was incorporated on 28th September, 1984 as a Private Limited Company. It was converted into a Public Limited Company on 1st July, 1992. The Company is presently engaged in the manufacture of MNI(300 TPA), MTZ (96 TPA), TNZ (84 TPA), DMZ (90 TPA) and Isoniazid (INH) (96 TPA). The Company started its commercial production is March 1987 at G.I.D.C. Industrial Estate, Sarigam, Dist. Valsad, Gujarat. This project was put up with financial assistance from Gujarat State Finance Corporation (GSFC) and Gujarat Industrial Investment Corporation (GIIC). The Company now proposes to expand the capacities for the above products, except INH and also proposes to set up a new plant for the manufacture of Glyoxal and Ammonium Sulphate. The Company has been consistently making profits and has maintained an unbroken dividend record since the year 1990-91. The Company is a part of the Alchemie Group of Companies. The Company is promoted by Mr. Chandrakant V.Gogri, Mr.Rajendra V.Gogri and Mr. Shantilal T. Shah. Mr. P.M. Patil and Mr. S. P. Nachane joined the Group in 1981. The Alchemie Group is a professionally managed, multi-product, multilocation Group comprising 24 manufacturing units with a total turnover of over Rs.100 crores for the year 1991-92. The products of the Group, exceeding 40, range from industrial chemicals and dye intermediates to bulk drugs and fine chemicals. The Group's customer list includes most of the leading chemical companies in the country. The Group's turnover and profits have increased five-fold in the last 5 years. It also recorded an export turnover of more than Rs. 30 crores in the year 1991-92. The Group units export products mainly to the general currency areas such as USA, UK, Switzerland and Germany. 2000 - The Company proposed to acquire 15,31,000 No. of equity shares of Alchemie Organics Ltd 33.44 per cent of the total paid-up capital of AOL held by the other promoters. 2002-Gauri Balankhe appointed as Compliance Officer of Aarti Drugs. 2004 -Aarti Drugs Ltd. has informed that the Company has changed its Registrar and Share Transfer Agent and Depository interface for Handling Depository related operations by appointing M/s Sharepro Services in place of M/s R & D Consultants Ltd w.e.f. January 16, 2004 subject to completion of necessary formalities as maybe prescribed in this regard. The address and telephone number of M/s Sharepro Services for all investors related services are as under: 1. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai 400 021, Tel nos : 22881569, 22884527. 2. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Satam Estate, 3rd Floor, Above Bank of Baroda, Chakla, Andheri (East), Mumbai 400 099, Tel nos : 28215168, 28319828; Fax nos : 28375646. -Aarti bags European certification for three drugs -Delist from Ahmedabad Stock Exchange (ASE) with effect from October 15, 2004. 2006 -Aarti Drugs enters into JV with API Manufacturing Chinese Company - Aarti Drugs Ltd. has informed that Mr. Prakash Khedekar, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from October 31, 2006. Further, Mrs. Mona Patel, possessing requisite qualifications, has been appointed as Company Secretary & Compliance Officer of the Company with effect from November 01, 2006. 2009 - Aarti Drugs Ltd has has appointed Shri Krishnacharya Govindacharya Akamanchi & Prof. Sudhir Prakash B. Sawant as Independent Directors of the Company. 2010 -Aarti Drugs has recommended dividend of Rs. 5/- (50%) per share 2011 -Mr. Sunny D. Pagare, has been appointed as Company Secretary & Compliance Officer of the Company -Aarti Drugs has recommended Final Dividend of Rs. 2.5 /-per share (25%) 2012 -Mr. Adhish P. Patil, has been appointed as Chief Financial Officer of the Company -Aarti Drugs has declared Final dividend Rs. 3.00 (30%) per share 2013 -Aarti Drugs has recommended a Final Dividend of Rs. 4/- per share on Equity Shares of Rs. 10/- each. 2014 -Aarti Drugs has commenced the new R&D center at MIDC Tarapur. -Aarti Drugs has recommended a Final dividend @ Rs. 5.50 ps. (55%) per share. 2015 -Aarti Drugs Ltd has will participate at 'Centrum Pharma Day' Investor Conference -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 1:1. 2020 -The Company has issued Bonus Shares in the Ratio of 3:1. 2023 -Aarti Drugs Limited won Pharmexcil Outstanding Exports Awards 2021-22"". 2024 -The Company Initiating Commercial Production of Dermatology Product at New Facility in Tarapur, Maharashtra"".
Aarti Drugs Limited was incorporated on 28th September, 1984 as a Private Limited Company. It was converted into a Public Limited Company on 1st July, 1992. The Company is presently engaged in the manufacture of MNI(300 TPA), MTZ (96 TPA), TNZ (84 TPA), DMZ (90 TPA) and Isoniazid (INH) (96 TPA). The Company started its commercial production is March 1987 at G.I.D.C. Industrial Estate, Sarigam, Dist. Valsad, Gujarat. This project was put up with financial assistance from Gujarat State Finance Corporation (GSFC) and Gujarat Industrial Investment Corporation (GIIC). The Company now proposes to expand the capacities for the above products, except INH and also proposes to set up a new plant for the manufacture of Glyoxal and Ammonium Sulphate. The Company has been consistently making profits and has maintained an unbroken dividend record since the year 1990-91. The Company is a part of the Alchemie Group of Companies. The Company is promoted by Mr. Chandrakant V.Gogri, Mr.Rajendra V.Gogri and Mr. Shantilal T. Shah. Mr. P.M. Patil and Mr. S. P. Nachane joined the Group in 1981. The Alchemie Group is a professionally managed, multi-product, multilocation Group comprising 24 manufacturing units with a total turnover of over Rs.100 crores for the year 1991-92. The products of the Group, exceeding 40, range from industrial chemicals and dye intermediates to bulk drugs and fine chemicals. The Group's customer list includes most of the leading chemical companies in the country. The Group's turnover and profits have increased five-fold in the last 5 years. It also recorded an export turnover of more than Rs. 30 crores in the year 1991-92. The Group units export products mainly to the general currency areas such as USA, UK, Switzerland and Germany. 2000 - The Company proposed to acquire 15,31,000 No. of equity shares of Alchemie Organics Ltd 33.44 per cent of the total paid-up capital of AOL held by the other promoters. 2002-Gauri Balankhe appointed as Compliance Officer of Aarti Drugs. 2004 -Aarti Drugs Ltd. has informed that the Company has changed its Registrar and Share Transfer Agent and Depository interface for Handling Depository related operations by appointing M/s Sharepro Services in place of M/s R & D Consultants Ltd w.e.f. January 16, 2004 subject to completion of necessary formalities as maybe prescribed in this regard. The address and telephone number of M/s Sharepro Services for all investors related services are as under: 1. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai 400 021, Tel nos : 22881569, 22884527. 2. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Satam Estate, 3rd Floor, Above Bank of Baroda, Chakla, Andheri (East), Mumbai 400 099, Tel nos : 28215168, 28319828; Fax nos : 28375646. -Aarti bags European certification for three drugs -Delist from Ahmedabad Stock Exchange (ASE) with effect from October 15, 2004. 2006 -Aarti Drugs enters into JV with API Manufacturing Chinese Company - Aarti Drugs Ltd. has informed that Mr. Prakash Khedekar, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from October 31, 2006. Further, Mrs. Mona Patel, possessing requisite qualifications, has been appointed as Company Secretary & Compliance Officer of the Company with effect from November 01, 2006. 2009 - Aarti Drugs Ltd has has appointed Shri Krishnacharya Govindacharya Akamanchi & Prof. Sudhir Prakash B. Sawant as Independent Directors of the Company. 2010 -Aarti Drugs has recommended dividend of Rs. 5/- (50%) per share 2011 -Mr. Sunny D. Pagare, has been appointed as Company Secretary & Compliance Officer of the Company -Aarti Drugs has recommended Final Dividend of Rs. 2.5 /-per share (25%) 2012 -Mr. Adhish P. Patil, has been appointed as Chief Financial Officer of the Company -Aarti Drugs has declared Final dividend Rs. 3.00 (30%) per share 2013 -Aarti Drugs has recommended a Final Dividend of Rs. 4/- per share on Equity Shares of Rs. 10/- each. 2014 -Aarti Drugs has commenced the new R&D center at MIDC Tarapur. -Aarti Drugs has recommended a Final dividend @ Rs. 5.50 ps. (55%) per share. 2015 -Aarti Drugs Ltd has will participate at 'Centrum Pharma Day' Investor Conference -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 1:1. 2020 -The Company has issued Bonus Shares in the Ratio of 3:1. 2023 -Aarti Drugs Limited won Pharmexcil Outstanding Exports Awards 2021-22"". 2024 -The Company Initiating Commercial Production of Dermatology Product at New Facility in Tarapur, Maharashtra"".
Read More
Parent Organisation
Aarti Drugs Ltd.
Founded
28/09/1984
Managing Director
Mr.Rashesh C Gogri
NSE Symbol
AARTIDRUGSEQ
FAQ
The current price of Aarti Drugs Ltd is ₹ 340.20.
The 52-week high for Aarti Drugs Ltd is ₹ 344.85 and the 52-week low is ₹ 332.30.
The market capitalization of Aarti Drugs Ltd is currently ₹ 3105.01. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Aarti Drugs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Aarti Drugs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Aarti Drugs Ltd shares.
The CEO of Aarti Drugs Ltd is Mr.Rashesh C Gogri, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.